Image by monsitj
Outlook Therapeutics (NASDAQ:OTLK) witnessed an impressive 13% surge in its stock value subsequent to a noteworthy upgrade by Chardan. The investment firm’s decision to elevate the stock to a buy rating was underpinned by the company’s recent private placement and the full cash exercise of associated warrants.
The financial specialists at Chardan expressed confidence in Outlook Therapeutics’ ability to allocate necessary funds for the ongoing NORSE 8 study, resubmit its Biologics License Application for Lytenava, and provide comprehensive backing for the potential launch of the drug, should it receive regulatory approval.
Asserting their optimism, the analysts at Chardan stated, “With the financial overhang mostly behind, and with clarity on the regulatory requirement for the Lytenava BLA resubmission, Chardon believes the risk/reward for OTLK is now favorable.”
Furthermore, Chardan has set a price target of $3 for the stock, reinforcing its bullish sentiment on Outlook Therapeutics’ future prospects.
Exploring Outlook Therapeutics’ Potential
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
